Follicular Lymphoma Clinical Trials

A listing of 56 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

1 - 12 of 56

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 56 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Learn More

Featured Trial

Healthy Volunteer Clinical Studies

Recruiting

Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.

Conditions:

Healthy

Healthy Volunteers

Learn More

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801

Recruiting

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More

Gender:

All

Ages:

Between 0 years and 38 years

Trial Updated:

01/24/2024

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma

Learn More ›

A Study of Mosunetuzumab in People With Follicular Lymphoma

NCT05389293

Recruiting

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Gender:

All

Ages:

18 years and above

Trial Updated:

06/21/2024

Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations

Conditions: Follicular Lymphoma, Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. Cohort A: Participants with relapsed or refractory MCL rel... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

06/21/2024

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +105 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008, Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics (, Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), São Paulo, Sao Paulo

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 (, Rio de Janeiro, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0, London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena, Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Region M. De Santiago

Clínica Inmunocel ( Site 1910), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Galilee Medical Center ( Site 0710), Nahariya, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron, Bologna, Emilia-Romagna

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Lazio

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant, Alessandria, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital- Isehara Campus ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital- Osakasayama Campus ( Site 1102), Osaka-sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Japanese Foundation for Cancer Research ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

Centro Medico Monte Carmelo ( Site 1702), Arequipa, Ariqipa

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Sit, Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

2CA BRAGA ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Cataluna

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( S, Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, England

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

The Christie NHS Foundation Trust ( Site 7007), Manchester, Not set

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

NCT04745559

Recruiting

The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.

Gender:

All

Ages:

18 years and above

Trial Updated:

06/19/2024

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL), Follicular Lymphoma

Learn More ›

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT06043323

Recruiting

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

Gender:

All

Ages:

18 years and above

Trial Updated:

06/18/2024

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Follicular Lymphoma

Learn More ›

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma

NCT04224493

Recruiting

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

06/12/2024

Locations: Southern Cancer Center, Mobile, Alabama +161 locations

Southern Cancer Center, Mobile, Alabama

Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona

TOI - Clinical Research, Cerritos, California

UCSF Fresno, Clovis, California

UC San Diego Health Sciences, La Jolla, California

UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California

Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado

St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado

SCL Health Lutheran Medical Center, Greeley, Colorado

Cancer Specialists of North Florida, Fleming Island, Florida

Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida

Mayo Clinic - Cancer Clinical Research Office, Jacksonville, Florida

Mayo Clinic, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida

BRCR Medical Center, INC, Plantation, Florida

Florida Cancer Specialists, Saint Petersburg, Florida

Florida Cancer Specialists - Panhandle, Tallahassee, Florida

H Lee Moffitt Cancer Center and Research Institute I, Tampa, Florida

Florida Cancer Specialists & Research Institute (FCS) - Atlantis, West Palm Beach, Florida

Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii

University of Chicago, Chicago, Illinois

Illinois Cancer Specialists, Niles, Illinois

June E. Nylen Cancer Center, Sioux City, Iowa

The University of Kansas Cancer Center, Overland Park, Kansas

University of Maryland, Baltimore, Maryland

The office of Frederick P. Smith, MD, P.C., Chevy Chase, Maryland

Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

St. Joseph Mercy Hospital, Ypsilanti, Michigan

Mayo Clinic - Rochester, Rochester, Minnesota

Saint Louis University Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Astera Cancer Care, East Brunswick, New Jersey

Astera Cancer Center, East Brunswick, New Jersey

Regional Cancer Care Associates-Freehold, Freehold, New Jersey

Hackensack University Medical John Theurer Cancer Center, Hackensack, New Jersey

Regional Cancer Care Associates LLC - Howell, Howell, New Jersey

Regional Cancer Care Associates LLC - Little Silver, Little Silver, New Jersey

New Mexico Cancer Care Alliance, Albuquerque, New Mexico

New York Oncology Hematology, P.C., Albany, New York

Northwell Health/Monter Cancer Center, Lake Success, New York

Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York

Columbia U - Herbert Irving Comprehensive Cancer Center, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Hematology Oncology Associates of Rockland, P.C., Nyack, New York

Messino Cancer Center, Asheville, North Carolina

Levine Cancer Institute - Concord, Concord, North Carolina

FirstHealth of the Carolinas, Pinehurst, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio

Willamette Valley Cancer Institute and Research Center - Oncology, Eugene, Oregon

University of Pittsburgh Medical Center - Oncology, Pittsburgh, Pennsylvania

Western Pennsylvania Hospital Hematology & Cellular Therapy, Pittsburgh, Pennsylvania

Tennessee Oncology, PLLC, Chattanooga, Tennessee

University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee

Texas Oncology - Amarillo, Amarillo, Texas

Texas Oncology-Austin Midtown, Austin, Texas

Texas Oncology - Medical City Dallas Pediatric Hematology, Dallas, Texas

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Millennium Physicians - Oncology, Houston, Texas

Texas Oncology, Plano, Texas

Mays Cancer Center, San Antonio, Texas

UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas

USO Texas Oncology - Tyler, Tyler, Texas

Texas Oncology- Weslaco, Weslaco, Texas

Utah Cancer Specialists/ IHO Corp, Salt Lake City, Utah

Huntsman Cancer Institute; The University of Utah, Salt Lake City, Utah

Peninsula Cancer Institute, Chesapeake, Virginia

Virginia Cancer Specialists, Gainesville, Virginia

Oncology and Hematology Associates of Southwest Virginia Inc., Roanoke, Virginia

MC Rockwood Cancer Bl Specialty Ctr - North, Spokane, Washington

Yakima Valley Memorial Hospital - North Star Lodge Cancer Center, Yakima, Washington

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Centre, Bedford Park, South Australia

Monash Health, Clayton, Victoria

Barwon Health, University Hospital Geelong, Geelong, Victoria

Hollywood Private Hospital, Nedlands, Western Australia

CHU Dinant Godinne UCL Namur, Yvoir, Namur

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant

University Health Network Princess Margaret Hospital, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, Quebec

Sir Mortimer B Davis/Jewish General Hospital, Montréal, Quebec

Fujian Medical University Union Hospital, Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Henan Provincial People's Hospital, Zhengzhou, Henan

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First Bethune Hospital of Jilin University, Changchun, Jinlin

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

Shanxi Bethune Hospital, Taiyuan, Shanxi

Peking University Third Hospital, Beijing, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque, Pessac Cedex, Aquitaine

CHRU Brest Hôp Morvan, Brest, Bretagne

Institut Bergonie, Bordeaux, Gironde

Centre Hosp Mulh Hop Emile Muller, Mulhouse, Haut-Rhin

Centre Henri Becquerel, Rouen, Haute-Normandie

CHU de Limoges Dupuytren, Limoges, Haute-Vienne

CHU de Grenoble - Hopital Albe, La Tronche, Isere

CHU de Nantes - Hematologie, Nantes, Loire-Atlantique

CHRU de Lille Hop Claude Huriez, Lille, Nord

Centre Hospitalier Le Mans, Le Mans, Sarthe

CHRU de Besançon- Hopital Jean Minjoz, Besancon, Not set

CHU Caen, Caen, Not set

CHU de Clermont-Ferrand, site Estaing, Clermont-Ferrand, Not set

L'Hôpital Privé Confluent, Nantes, Not set

Hopital Saint Louis, Paris, Not set

CHU de Nancy Brabois, Vandœuvre-lès-Nancy, Not set

Centre Hospitalier Bretagne Atlantique, Vannes, Not set

Hopital Henri Mondor - Hemopathies Lymphoides, Créteil, Île-de-France

Diakoneo Diak Schwaebisch Hall gGmbH, Schwäbisch Hall, Baden-Württemberg

Klinikum Der Universität München AöR, München, Bayern

Klinikum rechts der Isar der Technischen Universitat Muenche, München, Bayern

Universitätsmedizin Mainz, Mainz, Hessen

Universitaetsklinikum Bonn AöR, Bonn, Nordrhein-Westfalen

Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein-Westfalen

Städt. Krankenhaus Kiel, Kiel, Schleswig-Holstein

Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar

Semmelweis Egyetem Általános Orvostudományi Kar, Budapest, Not set

Országos Onkológiai Intézet, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai és Infektologiai Intezet, Budapest, Not set

AOU Federico II, Napoli, Campania

Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Meldola, Forli-Cesena

ASST Spedali Civili di Brescia, Brescia, Not set

PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, Not set

AOU Careggi, Firenze, Not set

Catholic University Of Sacred Heart, Roma, Not set

Azienda Ospedaliera Santa Maria di Terni, Terni, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp]

Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Mazowieckie

Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie

Pratia Onkologia Katowice, Katowice, Not set

Pratia MCM Krakow, Kraków, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Słupsk, Not set

MICS Centrum Medyczne Torun, Torun, Not set

Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Cataluny

Hospital Costa del Sol, Marbella, Málaga

Hospital Del Mar, Barcelona, Not set

Hospital Univ. Infanta Leonor, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Western General Hospital - Haematology, Edinburgh, Edinburgh, City Of

Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, London City

St Bartholomew's Hospital Barts Health NHS Trust, London, London, City Of

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

Learn More ›

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

NCT04186520

Recruiting

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

Gender:

All

Ages:

Between 18 years and 80 years

Trial Updated:

06/08/2024

Locations: Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin

Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma

Learn More ›

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Recruiting

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Gender:

All

Ages:

18 years and above

Trial Updated:

06/05/2024

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +83 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Mayo Clinic Phoenix, Phoenix, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California

Valkyrie Clinical Trials, Los Angeles, California

UCLA Santa Monica Cancer Care, Santa Monica, California

Stanford Medicine, Stanford, California

Uchealth North, Fort Collins, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Tampa General Hospital Cancer Institute, Tampa, Florida

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Norton Cancer Institute Pavilion, Louisville, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

American Oncology Partners of Maryland Pa, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Nebraska Cancer Specialists, Grand Island, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Summit Medical Group, Florham Park, New Jersey

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Md Anderson Cancer Center, Houston, Texas

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Concord Repatriation General Hospital, Concord, New South Wales

Princess Alexandra Hospital, Brisbane, Queensland

St Vincents Hospital Melbourne, Fitzroy, Victoria

Peninsula Private Hospital, Frankston, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Linear Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Instituto de Pesquisa Em Saude Da Universidade de Caxias Do Sul, Caxias do Sul, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Real E Benemerita Associacao Portuguesa de Sao Paulo, Sao Paulo, Not set

Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, Not set

Hospital Nove de Julho Dasa, Sao Paulo, Not set

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, Not set

Tom Baker Cancer Center, Calgary, Alberta

Chu de Quebec Universite Laval, Quebec, Not set

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Hopital Estaing, Clermont Ferrand, Not set

Chu Henri Mondor, Creteil, Not set

Hopital Claude Huriez Chu Lille, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Montpellier Hopital Saint Eloi, Montpellier Cedex, Not set

Hopital de La Pitie Salpetriere, Paris, Not set

Centre Henri Becquerel, Rouen Cedex, Not set

Arensia Exploratory Medicine Llc, Tbilisi, Not set

Universitaetsklinikum Schleswig Holstein Campus Luebeck, Luebeck, Not set

Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale San Raffaele, Milano, Not set

Istituto Europeo Di Oncologia, Milano, Not set

Niguarda Cancer Center Division of Hematology, Milano, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

Centroricerche Cliniche Di Verona Srl, Verona, Not set

Inje University Busan Paik Hospital, Busan, Busan Gwang'yeogsi

Pusan National University Hospital, Busan, Busan Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Md Anderson Cancer Center Madrid Spain, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sahlgrenska University Hospital Hematology, Goteborg, Not set

Karolinska Universitetssjukhuset Solna, Stockholm, Not set

Uppsala Akademiska Sjukhus, Uppsala, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

St Jamess University Hospital, Leeds, Not set

Freeman Hospital, NewCastle Upon Tyne, Not set

Derriford Hospital, Plymouth, Not set

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

Learn More ›

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019

Recruiting

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Gender:

All

Ages:

18 years and above

Trial Updated:

06/05/2024

Locations: Banner Health - MD Anderson Cancer Center, Gilbert, Arizona +14 locations

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

Learn More ›

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936

Recruiting

This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendamustine 90 mg/m2 IV on days 1 and 2 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up to three cycles. Following this, patients will receive tazemetostat twice daily on days 1-28 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

06/04/2024

Locations: Northwestern University, Chicago, Illinois +4 locations

Conditions: Follicular Lymphoma

Learn More ›

Clonal Evolution in Follicular Lymphoma

NCT03190928

Recruiting

Background: Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments. Objective: To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment. Eligibili... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

06/03/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Follicular Lymphoma

Learn More ›

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Recruiting

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Gender:

All

Ages:

18 years and above

Trial Updated:

05/31/2024

Locations: University of California San Diego, La Jolla, California +9 locations

Conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Chronic Lymphocytic Leukemia

Learn More ›

1 - 12 of 56